Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Anus Neoplasms, Astrocytoma, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Ependymoma, Esophageal Neoplasms, Glioblastoma, Glioma, Carcinoma, Hepatocellular, Oligodendroglioma, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Neuroectodermal Tumors, Primitive, Esthesioneuroblastoma, Olfactory, Glioma, Subependymal, Gliosarcoma, Breast Neoplasms, Male

NCT00536861 2008-05-29

Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer

Phase 1 Completed

11 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Clinical Trials

BM

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme

Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Ph I Dasatinib + Erlotinib in Recurrent MG

Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer